Articles

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.

Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.